Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HAEMONETICS CORPHAE · Entity 3953 | EVP and General Counsel | May 15, 2026 | May 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HAEMONETICS CORP
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,829 |
Last balance in matching sequence
After 2026-05-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-05-15 · Tax withholding · Disposed 2,913 · Balance 40,405 F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2: This number includes unvested RSUs previously reported. Row 2 · 2026-05-15 · Grant · Acquired 28,424 · Balance 68,829 F3: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. F4: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2: This number includes unvested RSUs previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
F2: This number includes unvested RSUs previously reported.
F3: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
F4: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 19, 2026 21:37 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 28,424 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000313143-26-000048 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,829 F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:37 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 2,913 | $56.29 | $163,972.77 |
DisclosureSEC source: 0000313143-26-000048 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,405 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 7,469 | $69.38 | $518,199.22 |
DisclosureSEC source: 0001127602-25-016497 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,252 F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 15,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-016497 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,721 F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 2,157 | $70.31 | $151,658.67 |
DisclosureSEC source: 0001127602-25-014945 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,478 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 12,317 | $0.00 Strike: $70.31 | $0.00 |
DisclosureSEC source: 0001127602-25-015058 · form4.xml · derivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,317 Underlying: Common Stock · 12,317 shares Expires 2032-05-16 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 5,689 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-015058 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,167 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2025 Filed Jun 13, 2025 20:26 UTC Amendment | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,626 | $0.00 Strike: $70.31 | $0.00 |
DisclosureSEC source: 0001127602-25-017498 · form4a.xml · derivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,626 Underlying: Common Stock · 14,626 shares Expires 2032-05-16 F5 · shares: On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of options awarded to be 12,317 instead of 14,626. This net increase of 2,309 options will be reflected in future filings by the reporting person. F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2025 Filed Jun 13, 2025 20:26 UTC Amendment | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 6,755 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-017498 · form4a.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,233 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · shares: On May 20, 2025, the reporting person filed a Form 4 that incorrectly showed the amount of RSUs awarded to be 5,689 instead of 6,755. This net increase of 1,066 RSUs, and the corresponding change in securities beneficially owned by the reporting person, will be reflected in future filings by the reporting person. F3 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F4 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 622 | $69.38 | $43,154.36 |
DisclosureSEC source: 0001127602-25-014945 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,635 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 29, 2024 Filed May 29, 2024 21:38 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 4,094 | $88.57 | $362,605.58 |
DisclosureSEC source: 0001127602-24-016810 · form4.xml · nonDerivative · entry 4 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,257 F4 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.29 to $88.92, inclusive. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 29, 2024 Filed May 29, 2024 21:38 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 8,896 | $87.86 | $781,602.56 |
DisclosureSEC source: 0001127602-24-016810 · form4.xml · nonDerivative · entry 3 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,351 F4 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.28 to $88.28, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) and (6) to this Form 4. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 28, 2024 Filed May 29, 2024 21:38 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 11,758 | $95.73 | $1,125,593.34 |
DisclosureSEC source: 0001127602-24-016810 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,247 F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 28, 2024 Filed May 29, 2024 21:38 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 24,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016810 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,005 F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,604 | $95.08 | $152,508.32 |
DisclosureSEC source: 0001127602-24-016164 · form4.xml · nonDerivative · entry 4 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,257 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023). F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,183 | $0.00 Strike: $95.73 | $0.00 |
DisclosureSEC source: 0001127602-24-016164 · form4.xml · derivative · entry 5 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,183 Underlying: Common Stock · 9,183 shares Expires 2031-05-17 F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 4,178 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-016164 · form4.xml · nonDerivative · entry 3 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,861 F4 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F5 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 669 | $95.73 | $64,043.37 |
DisclosureSEC source: 0001127602-24-016164 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,683 F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 17, 2024 Filed May 21, 2024 21:46 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,073 | $95.00 | $101,935.00 |
DisclosureSEC source: 0001127602-24-016164 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,352 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023). F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 16, 2024 Filed May 17, 2024 21:02 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 985 | $96.14 | $94,697.90 |
DisclosureSEC source: 0001127602-24-015872 · form4.xml · nonDerivative · entry 3 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,425 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023). F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2024 Filed May 17, 2024 21:02 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 446 | $94.80 | $42,280.80 |
DisclosureSEC source: 0001127602-24-015872 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,410 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:02 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 416 | $96.49 | $40,139.84 |
DisclosureSEC source: 0001127602-24-015872 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,856 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| October 20, 2023 Filed Oct 24, 2023 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 197 | $89.05 | $17,542.85 |
DisclosureSEC source: 0001127602-23-026198 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,272 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:37 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 3,541 | $83.34 | $295,106.94 |
DisclosureSEC source: 0001127602-23-016315 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,469 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 446 | $89.21 | $39,787.66 |
DisclosureSEC source: 0001127602-23-015931 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,010 F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,502 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015931 · form4.xml · derivative · entry 3 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,502 Underlying: Common Stock · 9,502 shares Expires 2030-05-15 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 4,205 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015931 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,456 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 12, 2023 Filed May 16, 2023 20:17 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 204 | $88.16 | $17,984.64 |
DisclosureSEC source: 0001127602-23-015739 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,251 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 20:35 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 180 | $80.39 | $14,470.20 |
DisclosureSEC source: 0001127602-22-024413 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,455 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,011 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · derivative · entry 7 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,553 Underlying: Common Stock · 1,011 shares Expires 2028-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 4,213 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · derivative · entry 6 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,213 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 3,464 | $0.00 Strike: $38.43 | $0.00 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · derivative · entry 5 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,464 shares Expires 2024-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 11,448 | $78.36 | $897,065.28 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · nonDerivative · entry 4 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,635 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.75, inclusive. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 1,011 | $56.57 | $57,192.27 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · nonDerivative · entry 3 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 4,213 | $41.64 | $175,429.32 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:50 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 3,464 | $38.43 | $133,121.52 |
DisclosureSEC source: 0001127602-22-022782 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:39 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 3,173 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001127602-22-022683 · form4.xml · derivative · entry 8 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,564 Underlying: Common Stock · 3,173 shares Expires 2028-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:39 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 14,231 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001127602-22-022683 · form4.xml · derivative · entry 7 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,213 Underlying: Common Stock · 14,231 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:39 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 11,154 | $0.00 Strike: $38.43 | $0.00 |
DisclosureSEC source: 0001127602-22-022683 · form4.xml · derivative · entry 6 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,464 Underlying: Common Stock · 11,154 shares Expires 2024-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:39 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 6,029 | $78.50 | $473,276.50 |
DisclosureSEC source: 0001127602-22-022683 · form4.xml · nonDerivative · entry 5 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,395 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.33 to $78.85, inclusive. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:39 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 27,769 | $77.76 | $2,159,317.44 |
DisclosureSEC source: 0001127602-22-022683 · form4.xml · nonDerivative · entry 4 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,424 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.33 to $78.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:39 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 3,173 | $56.57 | $179,496.61 |
DisclosureSEC source: 0001127602-22-022683 · form4.xml · nonDerivative · entry 3 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:39 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 14,231 | $41.64 | $592,578.84 |
DisclosureSEC source: 0001127602-22-022683 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:39 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 11,154 | $38.43 | $428,648.22 |
DisclosureSEC source: 0001127602-22-022683 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:29 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 277 | $62.60 | $17,340.20 |
DisclosureSEC source: 0001127602-22-017540 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,635 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:08 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 3,258 | $59.10 | $192,547.80 |
DisclosureSEC source: 0001127602-22-015363 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,912 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:40 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 14,208 | $0.00 Strike: $57.60 | $0.00 |
DisclosureSEC source: 0001127602-22-014969 · form4.xml · derivative · entry 3 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,208 Underlying: Common Stock · 14,208 shares Expires 2029-05-16 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:40 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 6,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-014969 · form4.xml · nonDerivative · entry 2 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,170 F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:40 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 196 | $56.10 | $10,995.60 |
DisclosureSEC source: 0001127602-22-014969 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,094 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 20:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 120 | $71.93 | $8,631.60 |
DisclosureSEC source: 0001127602-21-027702 · form4.xml · nonDerivative · entry 1 Basil Michelle L · CIK 0001699629 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,290 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.